National Research (NASDAQ:NRC) Sets New 1-Year Low at $40.81

National Research Co. (NASDAQ:NRC)’s stock price reached a new 52-week low during mid-day trading on Tuesday . The company traded as low as $40.81 and last traded at $42.42, with a volume of 31261 shares changing hands. The stock had previously closed at $41.72.

The firm has a market capitalization of $1.10 billion, a price-to-earnings ratio of 30.57 and a beta of 0.70. The firm has a fifty day moving average of $45.74. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.86 and a quick ratio of 1.69.

National Research (NASDAQ:NRC) last posted its quarterly earnings data on Tuesday, November 2nd. The company reported $0.38 EPS for the quarter. National Research had a return on equity of 48.54% and a net margin of 24.96%. The company had revenue of $37.77 million for the quarter.

The business also recently declared a quarterly dividend, which will be paid on Friday, January 14th. Investors of record on Thursday, December 30th will be given a dividend of $0.12 per share. The ex-dividend date of this dividend is Wednesday, December 29th. This represents a $0.48 annualized dividend and a yield of 1.11%. National Research’s dividend payout ratio (DPR) is 34.04%.

In other National Research news, major shareholder Amandla Mk Trust sold 50,000 shares of the business’s stock in a transaction dated Wednesday, November 3rd. The shares were sold at an average price of $50.06, for a total value of $2,503,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders sold a total of 55,074 shares of company stock valued at $2,776,743 in the last 90 days. Corporate insiders own 4.20% of the company’s stock.

A number of large investors have recently bought and sold shares of NRC. Comerica Bank increased its stake in shares of National Research by 2.9% in the 3rd quarter. Comerica Bank now owns 158,382 shares of the company’s stock valued at $6,861,000 after buying an additional 4,429 shares during the period. Bank of New York Mellon Corp boosted its holdings in National Research by 5.0% in the third quarter. Bank of New York Mellon Corp now owns 56,528 shares of the company’s stock valued at $2,383,000 after acquiring an additional 2,703 shares during the last quarter. Willis Investment Counsel raised its holdings in National Research by 18.0% during the 3rd quarter. Willis Investment Counsel now owns 56,206 shares of the company’s stock worth $2,370,000 after purchasing an additional 8,569 shares during the last quarter. BNP Paribas Arbitrage SA raised its holdings in National Research by 409.2% during the 3rd quarter. BNP Paribas Arbitrage SA now owns 2,495 shares of the company’s stock worth $105,000 after purchasing an additional 2,005 shares during the last quarter. Finally, Millennium Management LLC acquired a new position in National Research during the 3rd quarter valued at about $210,000. 43.82% of the stock is currently owned by hedge funds and other institutional investors.

National Research Company Profile (NASDAQ:NRC)

National Research Corp. engages in the provision of analytics and insights that facilitate patient, employee, and customer retention. It offers solutions that address specific needs around market insight, experience, transparency, and governance for healthcare providers, payers, and other healthcare organizations.

Featured Story: What is the S&P/TSX Index?

Receive News & Ratings for National Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for National Research and related companies with MarketBeat.com's FREE daily email newsletter.